Earkart Ltd

agm details

• AGM held on 15 July 2026; mode: physical with VC attendance.
• Notice issued on 23 June 2026.
• Cut-off date for eligibility: 8 July 2026.
• Voting window: 12 July 2026 09:00 IST to 14 July 2026 17:00 IST.
• Total shareholders on cut-off: 252.
• VC attendance at meeting: promoter 4, public 3.

voting results

• Remote e-voting results submitted; Scrutinizer's report enclosed.

IPO & Listing

• IPO completed and listed on BSE SME on 3 October 2025.
• IPO proceeds totaled ₹44.75 crore; ₹30.63 crore utilized; ₹14.12 crore unutilized in escrow.
• Promoter OFS of 3,34,000 equity shares; promoter IPO expenses advanced then recovered.
• Listing enhances governance framework and market visibility.

Financial Performance

• Total income ₹541.42m, up about 25.3% YoY.
• PAT ₹49.32m, down from ₹66.41m prior year.
• PBT ₹72.56m; profitability pressured by higher logistics and costs.

International Expansion

• US subsidiary Earkart Inc. incorporated Jan 2026; not operational by 31 Mar 2026.
• 100% owned; established to explore international opportunities.
• No revenue from USA subsidiary in FY26.

ESOP & Governance

• ESOP Scheme 2025 approved; Amended 2026; max 8,25,236 options.
• ESOP may extend to eligible employees of subsidiaries.
• Board/NRC to determine eligibility and vesting terms.
• Shares issued on exercise rank pari passu with existing shares.

Capital Structure & IPO Proceeds

• Equity capital post-IPO: 13,753,932 shares (₹137.54m).
• Promoter/promoter group held ~57.34% post-IPO.
• Unutilized IPO proceeds ₹14.12 crore in escrow.

Governance & Internal Controls

• Board meetings: 10 in FY2025-26; MD is Chair.
• Audit Committee met 7 times; independent chair.
• Secretarial Audit flagged UPSI recording in SDD and cost records.
• Form FC filing for USA subsidiary pending; corrective measures underway.

Risks & Outlook

• Opportunities: growing healthcare demand and digital distribution.
• Risks: regulatory changes, licensing, pricing, competition, supply chain, cybersecurity.
• Management focus: expand customer base, cost optimization, tech-enabled distribution.

Employees & CSR

• 58 employees as of 31 Mar 2026.
• CSR spend ₹9,14,633; PM CARES Fund and Smart Class for Diverse Disabilities.
• No sexual harassment complaints; no maternity issues.

AGM & Shareholding

• AGM on 15 July 2026; VC/OAVM; record date 8 July 2026.
• Ordinary business: reappointment of Rahul Salesha; special: ESOP amendments.
• Remote e-voting window: 12–14 July 2026.

AGM Details

• AGM held on 15 July 2026 at 3:00 PM IST via VC/OAVM.
• Record date: 08 June 2026; total shareholders on record: 252.

Key Resolutions

• Ordinary: Adoption of Audited Financial Statements and related reports.
• Ordinary: Re-appointment of Mr. Rahul Salesha as Director.
• Special: Ratification and approval of Amended and Restated ESOP Scheme 2025- Amended 2026.

Voting Status

• Voting results to be submitted later; final results not disclosed in filing.

Other Governance

• ESOP amendment subject to shareholder approval; no other changes disclosed.

Dematerialisation/rematerialisation status

• Certificate under Reg 74(5) for the quarter end date received from the RTA.

AGM Notice Details

• AGM: 5th AGM scheduled for 15 July 2026 at 3:00 PM IST via VC/OAVM.
• Newspaper notices published 25 June 2026 in Financial Express (English) and Jansatta (Hindi).
• Notice also published on the company's website.
• Notice issued under SEBI LODR Reg 30 and MCA/SEBI circulars.
• Corporate name updated to Earkart Limited from Earkart Private Limited.
• Company Secretary & Compliance Officer: Preeti Srivastava (Membership No. A31615).

Earkart Pharmaceuticals

• Proposed wholly owned subsidiary of Earkart Limited.
• Pharmaceuticals sector; intended to manufacture, promote, sell, and distribute products.
• Proposed authorised and paid-up share capital: Rs. 1,00,000 each.
• Turnover not applicable; entity is yet to be incorporated.
• Related party once incorporated; promoters and group companies have no other interest.
• Acquisition is 100% subscription to initial share capital in cash.
• Shares to be subscribed at face value of Rs. 10 each.
• No regulatory approvals or completion timeline specified.

Earkart Healthcare Services

• Proposed wholly owned subsidiary of Earkart Limited.
• Healthcare sector; intended to provide healthcare services.
• Proposed authorised and paid-up share capital: Rs. 1,00,000 each.
• Turnover not applicable; entity is yet to be incorporated.
• Related party once incorporated; promoters and group companies have no other interest.
• Acquisition is 100% subscription to initial share capital in cash.
• Shares to be subscribed at face value of Rs. 10 each.
• No regulatory approvals or completion timeline specified.

Board outcome

• 📍 Board approved audited standalone results for half year and year ended 31 March 2026.
• 📍 Board appointed internal auditor and secretarial auditor for FY 2026-27.

Audit opinion

• 📊 Statutory auditors issued an unmodified opinion on the standalone financial results.
• 📊 Results were prepared under Accounting Standards and Regulation 33 of SEBI Listing Regulations.

Accounting notes

• 📊 Half-year figures to 31 March 2026 are balancing figures between audited annual and prior unaudited numbers.
• 📊 Company operates in one primary segment: manufacture and distribution of modern hearing aids and accessories.
• 📊 EPS was computed under AS-20 and not annualised for the half year.
• 📊 No exceptional or extraordinary items were reported for the period.

Auditor appointments

• 📍 M/s Arvind Aggarwal & Associates was appointed internal auditor for FY 2026-27.
• 📍 M/s Nikita Kothari & Associates was appointed secretarial auditor for FY 2026-27.

Business

• Earkart manufactures and distributes modern hearing aids and related accessories.